These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18318773)

  • 21. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.
    Purkins L; Wood N; Ghahramani P; Greenhalgh K; Allen MJ; Kleinermans D
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2546-53. PubMed ID: 12121931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment.
    Kim A; Lee J; Shin D; Jung YJ; Bahng MY; Cho JY; Jang IJ
    Br J Clin Pharmacol; 2016 Aug; 82(2):389-98. PubMed ID: 27084997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects.
    Kim BH; Kim JR; Lim KS; Kim JW; Kim KP; Hong JH; Jang IJ; Shin SG; Yu KS; Tanaka T
    Clin Ther; 2009 Mar; 31(3):609-18. PubMed ID: 19393851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single- and Multiple-Dose Pharmacokinetics, Safety and Tolerability of Lurasidone in Healthy Chinese Subjects.
    Hu C; Wang Y; Song R; Yu C; Luo X; Jia J
    Clin Drug Investig; 2017 Sep; 37(9):861-871. PubMed ID: 28695535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
    Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
    Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
    Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
    CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic evaluation of a novel proton pump inhibitor, YH1885, in healthy volunteers.
    Yu KS; Bae KS; Shon JH; Cho JY; Yi SY; Chung JY; Lim HS; Jang IJ; Shin SG; Song KS; Moon BS
    J Clin Pharmacol; 2004 Jan; 44(1):73-82. PubMed ID: 14681344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A therapeutic confirmatory study to assess the safety and efficacy of Zydena (udenafil) for the treatment of erectile dysfunction in male patients with diabetes mellitus.
    Moon du G; Yang DY; Lee CH; Ahn TY; Min KS; Park K; Park JK; Kim JJ
    J Sex Med; 2011 Jul; 8(7):2048-61. PubMed ID: 21554549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
    Sidharta PN; Melchior M; Kankam MK; Dingemanse J
    Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteers.
    Moschetti V; Kim M; Sand M; Wunderlich G; Andersen G; Feifel U; Jang IJ; Timmer W; Rosenbrock H; Boland K
    Eur Neuropsychopharmacol; 2018 May; 28(5):643-655. PubMed ID: 29567399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
    Zhu X; Wu M; Wang H; Li H; Lin J; Peng Y; Hu Y; Li C; Ding Y
    Expert Opin Investig Drugs; 2021 May; 30(5):579-589. PubMed ID: 33682556
    [No Abstract]   [Full Text] [Related]  

  • 40. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction.
    Salem EA; Kendirci M; Hellstrom WJ
    Curr Opin Investig Drugs; 2006 Jul; 7(7):661-9. PubMed ID: 16869121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.